To improve the website's functionality, we use cookies, including third-party cookies. Read our Privacy Policy for more information
I AgreeAnalysis of Viral Antigens market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The global viral antigens market is estimated at US$ 175.9 billion in 2022 and is forecasted to expand at a high-value CAGR of 8.2% to reach a market size of US$ 388.1 billion by the end of 2032.
Viral antigens are gaining attention owing to advancements in microbiology as well as vaccine development, in which, North America is the most favorable market for manufacturers of viral antigens.
Report Attributes |
Details |
---|---|
Viral Antigens Market Size (2021A) |
US$ 159.4 Billion |
Estimated Market Value (2022E) |
US$ 175.9 Billion |
Forecasted Market Value (2032F) |
US$ 388.1 Billion |
Global Market Growth Rate (2022-2032) |
8.2% CAGR |
North America Market Share (2021) |
~ 49% |
Europe Market Growth Rate (2022-2032) |
~ 8.1% CAGR |
United States Market Growth Rate (2022-2032) |
~ 7.9% CAGR |
Market Share of Top 5 Companies |
~ 17.4% |
Key Companies Profiled |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The occurrence of viral diseases as well as the requirement for faster immunity boosting is fueling the need for the administration of viral antigens in the host body. Numerous outbreaks of infectious diseases caused by viruses, such as hepatitis, AIDS, influenza, and the recent COVID-19 virus, have created urgency in vaccine research and development. Additionally, investments in vaccine development by government authorities and key market players are also supporting the introduction and rising awareness of viral antigens.
These factors have amplified the sales of viral antigens during the historical period (2017-2021) at a CAGR of 7.7%.
Most of the newly established techniques, such as the electron microscopy workflow, are promising for advancements in viral research. For example, with the development of image systems, it is possible to capture an image in real time and produce immunoassay results that are efficient and reproducible.
In addition, electron microscopy is emerging as a potential technique to recognize viral antigens and determine their structural organization and localization within viruses and vaccines. Hence, rising awareness of electron microscopy among specialists in vaccine research and related stakeholders are guiding their focus to this category.
Fact.MR predicts that the global viral antigens market will be valued at US$ 388.1 billion by 2032, expanding at a CAGR of 8.2% over the decade.
Over the 2017-2021 historical period, the global viral antigens market progressed at a CAGR of 7.7%, and according to Fact.MR, a market research and competitive intelligence provider, the industry is expected to surge ahead at 8.2% CAGR through 2032.
Market share analysis of viral antigens based on detection technique and region. Under the detection technique segment, ELISA dominates with 31.6% market share in 2022.
“Advancements in Image Analysis Software & Informatics Platforms”
Technological developments such as the electron microscopy workflow are assisting in the speedy development of viral research activities. The possibility of capturing pictures and videos of viral antigen immunogenicity analysis in HD mode due to technological and scientific advancements is a key factor contributing to market growth.
Additionally, modern research has ensured the development of sophisticated automated tools that can capture superior quality HD images in various phases. Apart from this, differential cell analysis can be done with the help of these devices, which results in reproducible images in red and green fluorescent contrasting outlines.
As such, these are suitable tools that can be used for varied parallel applications in the viral antigens market.
“Intensifying Outbreaks of Virus-Borne Diseases”
In the previous decades, the entire world was facing the outbreak of several infectious viruses, which became a severe threat to global health and the economy. This scenario is not over yet, for which the COVID-19 pandemic is a big example. It is anticipated that the world will face the same situation in the future owing to changing viral protein structures and mutations.
Various factors such as globalization, urbanization, aging, international commerce, and climate change have supported the emergence, transmission, and spread of pathogens. As viral antigens play a vital role in boosting immunity, the outbreak of various infectious diseases will spur the global demand for viral antigens.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
“Less Immunogenicity than Inactivated Whole-virus Vaccines Lowering Market Value”
Every product or technology comes with some advantages as well as drawbacks, and viral antigens have their own drawbacks that limit their demand growth. As viral antigens are the proteins present on the surface of a virus, the evolving structure of a protein by the virus may require further production of new viral antigens. This repetitive procedure is costly as well as very time-consuming.
Also, inactivated whole-virus vaccines are undergoing treatments called attenuation that help improve the immunogenicity of the host body. Therefore, the advantage of whole-virus vaccines over viral antigens may limit the acceptance of viral antigens across regions over the years to come.
The viral antigens market in the United States is expected to expand at a CAGR of 7.9% from 2022 to 2032.
In North America, the U.S. is ruling the viral antigens market in 2022 due to high investments in R&D and the fast-growing technological sector. Apart from this, the presence of several key manufacturers of viral antigens is a supporting factor for the market growth in the United States. Rising cases of infectious diseases in the country are generating a huge need for viral antigens.
East Asia accounted for 10% share of the global viral antigens market at the end of 2021.
The growing population and high chances of spreading infectious diseases in East Asia and South Asia and the ASEAN regions are anticipated to make these opportunistic regions for the market players.
Furthermore, developing healthcare facilities as well as an increase in government initiatives will support viral antigens market growth in Japan. Also, rising investments in technology will drive market growth across the Asia Pacific region.
Enzyme-linked immunosorbent assay (ELISA) is the most popular and widely used tool for the diagnosis and detection of virus infection. This tool is gaining popularity as being specific, safe, and rapid owing to its capability of producing recombinant viral proteins.
Hence, the acceptance of ELISA for the recognition of viral antigens is anticipated to lead to it holding 31.6% share of the global market share and increase at a CAGR of 8.5% during the forecast period.
In terms of end user, viral antigens are segmented into blood banks, clinics, laboratories, diagnostic centers, and research institutes.
Hospitals are the key contributors to the sales of viral antigens and hold a majority of the share in the global market. The same trend is expected to be witnessed during the forecast period as well. The hospitals segment is projected to account for 28.8% share of the market by the end of 2032.
However, blood banks are the fastest-growing end-user segment in the global market. This segment is anticipated to grow at a CAGR of 11% during the assessment period.
Prominent viral antigen manufacturers are Microbix Biosystems Inc., Bio Rad Laboratories, Creative Diagnostics, Aalto Bio Reagents, ProSpec-Tany TechnoGene Ltd., The native antigen company, Meridian bioscience, Inbios, Rekom biotech, and Sekbio.
Technological improvements in the biopharmaceutical industry are providing substantial growth prospects for viral antigen suppliers. Additionally, manufacturers are focusing on new product launches and product development. Hence, the rise in new product launches and developments, including the introduction of numerous novel recombinant antigens for the growth of antibody tests for COVID-19, will hasten the development of the market.
Apart from organic tactics, key market players are also adopting inorganic growth strategies for business expansion and the generation of a high-revenue share in the market.
Fact.MR has provided detailed information about the price points of key manufacturers of viral antigens positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunities
Buy NowGet A Special pricing for start-ups and universities
Enquiry Before Buying- Humble, Yet Honored -
Revenue from the sales of viral antigens is anticipated to reach US$ 388.1 billion by 2032-end.
The ELISA detection technique accounts for 31.6% share of the global market.
The global viral antigens market is estimated at US$ 175.9 billion in 2022.
North America tops the global viral antigens market and accounts for 49.3% market share in 2022.
From 2017 to 2021, worldwide sales of viral antigens increased at 7.7% CAGR.